Back Clear search

The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XIV - Pleural involvement

XIV.o

Pleuroparenchymal fibroelastosis (PPFE)

XXII - Acute respiratory/cardiorespiratory failure

XXII.b

ARDS - Acute lung injury

XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.a

Pneumonitis (interstitial lung disease/ILD)
XXIV.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV.d

Acute eosinophilic pneumonia (AEP)
XXIV.k

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
XXIV.q

An area or areas of consolidation
XXIV.s

Lung nodule or nodules

XXVIII - Large airway involvement including UAO

XXVIII.a

Angioedema (may cause UAO, asphyxia and death)

XXX - Imaging features

XXX.e

Imaging: An area or areas of consolidation

XXXIII - Histopathology (for pulmonary pathology see in ‘Pneumotox’ (a free companion App)

XXXIII.y

Path: Acute fibrinous organizing pneumonia (AFOP-pattern)

XXXVI - Autoimmune syndromes - Systemic reactions or conditions

XXXVI.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

XXXIX - Rechallenge

XXXIX.e

Rechallenge may not necessarily lead to relapse of AE/ILD